This discrepancy is clinically relevant in the context of long-term treatment, particularly in adjuvant or neoadjuvant settings, and in patients with metastatic castration-sensitive prostate cancer, who may undergo GnRH therapy for periods exceeding five years. This evidence concerns the gene GNRH1 and prostate carcinoma.